Comparative Pharmacology
Head-to-head clinical analysis: DESOGESTREL AND ETHINYL ESTRADIOL versus ESTROGENIC SUBSTANCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESOGESTREL AND ETHINYL ESTRADIOL versus ESTROGENIC SUBSTANCE.
DESOGESTREL AND ETHINYL ESTRADIOL vs ESTROGENIC SUBSTANCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desogestrel is a progestin that suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol is an estrogen that provides negative feedback on the hypothalamic-pituitary axis, further suppressing ovulation and altering cervical mucus and endometrial lining to reduce sperm penetration and implantation.
Estrogens bind to and activate nuclear estrogen receptors (ERα and ERβ), leading to gene transcription and regulation of reproductive tissues and secondary sexual characteristics.
One tablet (0.15 mg desogestrel/0.03 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo tablets, then repeat cycle.
0.3 to 1.25 mg orally once daily; 25 to 100 mcg transdermal patch applied twice weekly; 0.5 to 2 mg vaginal cream daily for 3 weeks then 1 week off.
None Documented
None Documented
Desogestrel: terminal half-life 23-27 hours (active metabolite etonogestrel); clinically allows once-daily dosing. Ethinyl estradiol: terminal half-life 12-15 hours (range 10-20 hours) with biphasic elimination; supports daily administration.
Terminal elimination half-life is approximately 13-27 hours for endogenous estrogens, with clinically therapeutically relevant metabolites having half-lives up to 24-36 hours, allowing once-daily dosing.
Desogestrel: primarily renal (approximately 60% as metabolites), 30% fecal. Ethinyl estradiol: primarily renal (approximately 40% as glucuronide conjugates), 60% fecal.
Primarily renal as glucuronide and sulfate conjugates; approximately 60-80% excreted in urine, 10-30% in feces via biliary elimination.
Category D/X
Category C
Estrogen
Estrogen